Publications by authors named "Stephen Lott"

Claim this Profile
U
Understanding insurance coverage policies for incretin mimetics for weight management.
Dina H Griauzde, Eli W Carter, Lauren Oshman, Jonathan Gabison, Andrew Kraftson, Stephen Lott

Am J Manag Care· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Collaboration to transition members to preferred formulary dipeptidyl-peptidase-4 inhibitor.
Kelsey Ernst, Amy N Thompson, Amina Bensami, Hae Mi Choe, Stephen Lott

Am J Manag Care· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Examining the Effects of Whole Crop Wheat Silage on Ewe Performance during Late Gestation Compared to Traditional Grass Silage across Three Prolific Breed Types.
Jonathan T Higgins, Dermot Campion, Joe Jones, Stephen Lott, M Bridget Lynch

Animals (Basel)· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study.
Charitha Gowda, Stephen Lott, Matthew Grigorian, Dean M Carbonari, M Elle Saine

Open Forum Infect Dis· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eight-Week Outcomes of Ledipasvir/Sofosbuvir in Noncirrhotic Treatment-Naive Patients with Hepatitis C: Analysis of Pharmacy-Based Data.
Jennifer Andres, Stephen Lott, Kamran Qureshi

J Manag Care Spec Pharm· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.
Kris V Kowdley, Vinay Sundaram, Christie Y Jeon, Kamran Qureshi, Nyan L Latt, Stephen Lott

Hepatology· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Luteinizing hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and invasion in ovarian cancer cells.
Susanne W Warrenfeltz, Stephen A Lott, Travis M Palmer, Judy C Gray, David Puett

Mol Cancer Res· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis